A Phase 2 interventional study of Hemanext Red Blood Cell Processing System in Whole Blood Donation and Leukoreduction, sponsored by Hemanext. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-23.
Sponsored by Hemanext · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary goal of Hemanext. is to improve red cell storage through novel storage methods. Based on our review of the pertinent literature, there is substantial evidence suggesting that prolonged exposure to oxygen during storage results in oxidative damage to the red blood cells leading to decreased therapeutic potential. Therefore, removal of oxygen from red blood cell products prior to storage has potential to preserve the cells in a more physiologically relevant state.
Currently, Hemanext has focused on the design and development of a dual compartment bag system designated as the Hemanext Red Blood Cell Processing System. After standard processing of donated whole blood units into leukoreduced packed red blood cells (LR-RBCs) with the appropriate additive solutions, the LR-RBCs would then be placed in the oxygen reduction bag (ORB) which allows for the rapid diffusion of oxygen out of the blood, through a sterile, oxygen-permeable membrane, and into iron-based oxygen sorbents. After processing, the blood is transferred again from the ORB into the Hemanext storage bag (HSB) which will preserve the anaerobic state of the LR-RBC product for the duration of cold storage.
Hemanext has conducted preliminary storage tests to ascertain the effects of anaerobic storage on overall blood health in various storage solutions. The research team has focused primarily on percent hemolysis, which is mandated by the FDA to remain below 1% for the duration of storage, as well as ATP and 2,3-DPG levels.
In vitro and in vivo performance of O2/CO2 reduced red blood cells produced with the Hemanext System will be used to demonstrate the acceptability the final product for clearance. To accomplish this, the study will require a total of 100 studyevaluable donors. completing the study. The study entails a randomized, paired, 2-x-2 crossover design where every study donor (n = 10093) evaluable study donors who completes the study will donate a total of two whole blood units with individual units being donated at least 56 days (8 weeks) apart. One unit will be used as the test and the other unit will be used for the control. The order in which the IP and the CP will be used to collect, filter and store the whole blood and appropriate blood products (within the context of the crossover design) will be randomized.
Hemanext is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study donor must have consented to study participation by reviewing and having expressed understanding the site-respective IRB-approved form prior to undergoing any study related procedures.
21 CFR 50
Women of child-bearing age must not be pregnant as determined by a negative pregnancy test prior to each re-infusion. If acceptable by local procedures, or surgically sterile women may be exempt from the pregnancy testing requirement.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
Device: Hemanext Red Blood Cell Processing System
Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
% of Red Blood Cells With Hemolysis
Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.
Time frame: On day 42 of storage
Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells
The mean 24-hour, post-transfusion, in vivo red blood cell recovery.
Time frame: Day 42 of storage
% Red Blood Cells Recovered Post-Filtration
Percentage of red blood cells recovered after the filtration process.
Time frame: Post-Filtration on Day 0
| Milestone | Investigational Product First, Then Control Product | Control Product First, Then Investigational Product |
|---|---|---|
| Started | 48 | 52 |
| Completed | 40 | 45 |
| Not completed | 8 | 7 |
Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.
| % of Red Blood Cells with Hemolysis | Investigational Product | Control Product |
|---|---|---|
| % of Red Blood Cells With Hemolysis | 0.29 ± 0.168 | 0.29 ± 0.152 |
The mean 24-hour, post-transfusion, in vivo red blood cell recovery.
| % Recovery of Red Blood Cells | Investigational Product | Control Product |
|---|---|---|
| Dual Label 24 Hour In Vivo % Recovery of Red Blood Cells | 89.3 ± 5.81 | 85.8 ± 6.12 |
Percentage of red blood cells recovered after the filtration process.
| % of Red Blood Cells Recovered | Investigational Product | Control Product |
|---|---|---|
| % Red Blood Cells Recovered Post-Filtration | 92.3 ± 1.9 | 91.1 ± 4.31 |
Collected over Study-related adverse events are defined as those study participant-reported adverse events occurring within 24-hours of donation and/or transfusion. Non-study-related adverse events outside of these periods were not recorded unless they were of a nature to impact study participant evaluability, safety or data validity.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Investigational Product | 0/100 (0%) | 1/100 (1%) | 9/100 (9%) |
| Control Product | 0/100 (0%) | 1/100 (1%) | 9/100 (9%) |
| Event | Investigational Product | Control Product |
|---|---|---|
| AppendicitsInfections and infestations | 1/100 | 1/100 |
| Event | Investigational Product | Control Product |
|---|---|---|
| Light-headedness after donationInjury, poisoning and procedural complications | 4/100 | 4/100 |
| Bruising or pain on arm at blood donation siteInjury, poisoning and procedural complications | 4/100 | 4/100 |
| Subject called to say he had dizziness at work after donation.Injury, poisoning and procedural complications | 1/100 | 1/100 |
| Dizzyness after donationInjury, poisoning and procedural complications | 1/100 | 1/100 |
| Nausea after donationInjury, poisoning and procedural complications | 1/100 | 1/100 |
| Cardiac AblationCardiac disorders | 1/100 | 1/100 |
| Side PainInfections and infestations | 1/100 | 1/100 |
| Age, Continuous(years) | All Study Donors |
|---|---|
| Mean | 47.0 ± 15.0 |
| Sex: Female, Male(Participants) | All Study Donors |
|---|---|
| Female | 47 |
| Male | 53 |
| Ethnicity (NIH/OMB)(Participants) | All Study Donors |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 98 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Study Donors |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 10 |
| White | 88 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Mar 2019, 15 months.
Results were first posted in Mar 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hemanext